Small Cell Lung Cancer Research Roundup: Promising Clinical Trial Updates
Imdelltra (tarlatamab) significantly reduces the risk of death in patients with extensive‑stage SCLC and brain metastases, achieving an overall survival benefit compared with chemotherapy.
This blog post summarizes the most clinically promising updates from recent trials in extensive‑stage and relapsed/refractory small cell lung cancer (SCLC).
The data support continued use of Imdelltra (tarlatamab) in patients with brain metastases, addressing uncertainty about CNS efficacy of immune‑based therapies in SCLC.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells